Flying The Web For News.
  • 2024 Presidential Election
    2024 Presidential Election
  • Career Exam Study
    Career Exam Study
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm

Details
Category: Globe NewsWire News Distribution Service

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) in the United States District Court for the Middle District of North Carolina on behalf of all…


Posted: 2024-11-20 02:00:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

humacyte | press | release | alert | bragar


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm - Newscast

HUMA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Humacyte, Inc.

Mon, 18 Nov 2024 13:59:00 GMT On October 17, 2024, during market hours, the FDA released a Form 483 concerning Humacyte's Durham, North Carolina facility, which revealed a number of violations, including "no microbial quality ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humacyte, Inc. - HUMA

Sat, 16 Nov 2024 09:23:00 GMT On August 9, 2024, Humacyte issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of its Biologic License ...

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

Thu, 14 Nov 2024 05:00:00 GMT DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humacyte, Inc. - HUMA

Sun, 10 Nov 2024 09:00:00 GMT On August 9, 2024, Humacyte issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of its Biologic License ...

Humacyte, Inc. (HUMA) Q3 2024 Earnings Call Transcript

Fri, 08 Nov 2024 00:30:00 GMT Information presented on this call is contained in the press release we issued this morning and in our Form 10-Q, which after filing may be accessed from the Investors page of the Humacyte website.


Blow Us A Whistle